CN102276545B - Method for preparing epoxybutane compounds and intermediates thereof - Google Patents
Method for preparing epoxybutane compounds and intermediates thereof Download PDFInfo
- Publication number
- CN102276545B CN102276545B CN201010199114.5A CN201010199114A CN102276545B CN 102276545 B CN102276545 B CN 102276545B CN 201010199114 A CN201010199114 A CN 201010199114A CN 102276545 B CN102276545 B CN 102276545B
- Authority
- CN
- China
- Prior art keywords
- formula
- compound
- organic bases
- configuration
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 *C[C@]([C@](C*)O1)NC1=O Chemical compound *C[C@]([C@](C*)O1)NC1=O 0.000 description 3
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Abstract
The invention relates to the technical field of heterocyclic compounds, in particular to the preparation of epoxybutane compounds. The preparation method comprises the following steps of: performing a cyclization reaction of halomethyl alcohol compounds with 2S, 3S or 2R, 3R configuration and a chlorination reagent to obtain oxazolidinone derivatives with 4S, 5R or 4R, 5S configuration; protecting amino groups of the obtained oxazolidinone derivatives under alkaline conditions to obtain N-substituted oxazolidinone derivatives with 4S, 5R or 4R, 5S configuration; and performing an epoxidation reaction on the obtained N-substituted oxazolidinone derivatives under alkaline conditions to obtain the epoxybutane compounds with 2R, 3S or 2S, 3R configuration.
Description
Technical field
The present invention relates to heterogeneous ring compound technical field, particularly relate to butylene oxide ring compounds technical field.
Background technology
Human immunodeficiency virus (HIV) is the pathogenic agent causing acquired immune deficiency syndrome (AIDS) (AIDS), and Reyataz R (Atazanavir) is a kind of active drug being used for the treatment of acquired immune deficiency syndrome (AIDS).At present can by the butylene oxide ring compounds of 2R, 3S configuration be raw material to synthesize Reyataz R, the synthesis of Reyataz R can method in referenced patent W02008065490, and concrete route is as follows:
The method is with butylene oxide ring compounds (2R, 3S)-3-tert-butoxycarbonylamino-4-phenyl-1, 2-butylene oxide ring is raw material, carry out epoxidation ring-opening reaction with formula (9) compound and obtain formula (6) compound, formula (6) compound and (S)-2-(methoxy carbonyl amino)-3, 3-acid dimethyl is at I-hydroxybenzotriazole (DCC), 1, 3-dicyclohexylcarbodiimide (HOBt) is carried out condensation reaction under existing and is obtained formula (7) compound, formula (7) compound carries out debenzylation and obtains formula (8) compound under palladium carbon exists, formula (8) compound carries out amino substitution reaction with chloroformyl methyl esters and obtains final product Reyataz R under di-isopropyl second ammonia exists.
The synthetic method of current 2R, 3S configuration butylene oxide ring compounds is that raw material synthesizes mainly with the monochloromethyl ketone compounds of 3S configuration, method disclosed in patent EP1777213, and it is as follows that it announces route:
Wherein R is C
1~ C
10alkyl, C
6~ C
15phenyl or C
7~ C
20aralkyl.
Be specially (S)-N, N-dibenzyl benzene second ammonia ester compound (formula 1 compound) and methyl chloride lithium carry out substitution reaction and obtain (S)-3-dibenzyl amino-1-chloro-2-oxo-4-benzene butane (formula 2 compound), (S)-3-dibenzyl amino-1-chloro-2-oxo-4-benzene butane carries out reduction reaction under the effect of sodium borohydride class reductive agent, the racemization reduzate obtained obtains (2R after separation and purification, 3S)-3-dibenzyl amino-1-chlorine-2-hydroxyl-4-benzene butane, then (2R is obtained with sulfuric acid salify, 3S)-3-dibenzyl amino-1-chlorine-2-hydroxyl-4-benzene butane vitriol (formula 3 compound), (2R, 3S)-3-dibenzyl amino-1-chlorine-2-hydroxyl-4-benzene butane carries out catalytic reduction and obtains (2R under the effect of palladium carbon, 3S)-3-amino-1-chloro-2-oxo-4-benzene butane (formula 4 compound), (2R, 3S)-3-amino-1-chloro-2-oxo-4-benzene butane carries out protection with anhydrides compound to amino in the basic conditions and obtains 2R, formula (5) compound of 3S configuration, 2R, formula (5) compound of 3S configuration carries out ring in the basic conditions and is obtained by reacting 2R, butylene oxide ring compounds (the formula a of 3S configuration
2compound).
The route announced in patent EP1081133 is as follows:
Wherein Ra is alkyl or phenyl; A is C
1-C
10(replacement) alkane, C
6-C
15(replacement) aromatic base or C
7-C
20(replacement) aralkyl; X represents halogen atom.
Concrete operation method is monochloromethyl ketone compounds, namely formula (1-1) compound obtains the monochloromethyl alcohol compound of racemization under the effect of sodium borohydride class reductive agent, then (2R is obtained through separation and purification, 3S) the monochloromethyl alcohol compound (formula 1-2 compound) of configuration, (2R, 3S) the monochloromethyl alcohol compound of configuration carries out ring-closure reaction in the basic conditions, obtains epoxy compounds, i.e. formula (a
3) compound.
The shortcoming of patent EP1777213 route is, when preparing monochloromethyl ketone compound (formula 2 compound), use reagent methyl chloride lithium, methyl chloride lithium is very unstable, see that oxygen can burn immediately, need during operation to carry out at quite low temperatures, temperature range is-50 ~-100 DEG C, is difficult to operation during industrialization, the common drawback of patent EP1777213 and patent EP1081133 is, all sodium borohydride will be used when reducing monochloromethyl ketone compound, lithium borohydride class reductive agent, boron hydrogen class reductive agent has very large toxicity, inflammable and explosive, preservation is required strict, the easy moisture absorption, the reduzate monochloromethyl alcohol compound generated is mixture, i.e. 2S, 3S and 2R, the compound of 3S two kinds of configurations, needs carry out fractionation and further purifying can obtain pure 2R, the monochloromethyl alcohol compound of 3S configuration, and 2S, the monochloromethyl alcohol compound of 3S configuration but not can be good at being utilized, this just causes low yield, high cost, not easily carry out scale operation.
In patent EP1050532, also disclose the synthetic method of another synthesis 2R, 3S configuration butylene oxide ring compounds simultaneously, announce one of route as follows:
Wherein Rb
1for (replacement) phenyl, alkyl, or p-nitrophenyl; Rb
2for tertbutyloxycarbonyl, carbobenzoxy-(Cbz) or to methoxybenzyloxycarbonyl; Rb
3for arylsulfonyl or alkane alkylsulfonyl; X
1for halogen.
Concrete operation method is 2S; formula (2-1) compound of 3S configuration and aryl sulfonyl halide effect are protected hydroxyl; obtain formula (2-2) compound; formula (2-2) compound obtains oxazolidone analog derivative under the effect of the highly basic such as sodium trichloroacetate or sodium trifluoroacetate; i.e. formula (2-3) compound; oxazolidone analog derivative obtains 2R under the effect of mineral alkali, the epoxy compounds of 3S configuration, i.e. formula (a
4) compound.
This method can utilize 2S, the monochloromethyl alcohol compound of 3S configuration, and tool has greatly improved, but it also has some shortcomings, the irritant stench of sulfonyl halides compound simultaneously, and most water insoluble, and post-processing difficulty is large; Sodium trichloroacetate, sodium trifluoroacetate quasi-alkali is irritant, need the reagent of benzene class or halo as solvent, and they all has very large toxicity by during formula (2-2) compounds accepted way of doing sth (2-3) compound; Comprehensive whole piece route cost is very high, causes technology poor feasibility.
In view of the medicine prospect that Reyataz R is good, in prior art, existing resource utilization ratio is low, agents useful for same toxicity is large, and environmental pollution is serious, technology high in cost of production shortcoming, need to develop a kind of 2R more having pharmaceutical value, the synthetic method of the epoxy compounds of 3S configuration, particularly will develop a kind of 2S do not made full use of will existed in existing resource, and the monochloromethyl alcohol compound of 3S configuration is raw material, and convert it into 2R, the efficient synthesis of the epoxy compounds of 3S configuration.
Summary of the invention
The object of the invention is with the monochloromethyl alcohol compound of the 2S do not made full use of in existing resource, 3S configuration be raw material to synthesize 2R, the method for the butylene oxide ring compounds of 3S configuration; The method in technical solution of the present invention can be utilized in addition, by the monochloromethyl alcohol compound of 2R, 3R configuration be raw material to synthesize 2S, the butylene oxide ring compounds of 3R configuration.
In order to realize above-mentioned two objects, the technical solution used in the present invention is as follows:
Scheme one: a kind of synthetic method of butylene oxide ring compounds of 2R, 3S configuration, with chemical equation represent as:
Steps A:
Step B:
Step C:
Scheme two: a kind of synthetic method of butylene oxide ring compounds of 2S, 3R configuration, with chemical equation represent as:
Step D:
Step e:
Step F:
Wherein R
1for amino acid side chain, R
2for protecting group, X is leavings group.
R
1be specially, aromatic base, substituted-phenyl, alkyl, aralkyl; R
2be specially alkyl, aralkyl, alkylene, alkoxyphenyl radical; X is halogen.
R
1be preferably phenyl, p-nitrophenyl, C
1-C
10alkyl or substituted alkyl, p-methylphenyl; R
2be preferably the tertiary butyl, benzyl, to methoxybenzyl, allyl group; X is preferably Cl, Br.
Concrete reaction process is as follows:
Steps A or step D: formula (d-1) or formula (d-2) compound carry out ring and react corresponding obtaining formula (c-1) or formula (c-2) compound with chlorination reagent.
Wherein said chlorination reagent can be SOCl
2; The mole dosage of described chlorination reagent and formula (d-1) or formula (d-2) is than being (2 ~ 20): 1, is preferably (3 ~ 10): 1.
The reaction solvent of this reaction process is ethers, is preferably tetrahydrofuran (THF), methyl tertiary butyl ether; Described solvent load is 10 ~ 50 times of described formula (d-1) or formula (d-2) compound.
The temperature of reaction of described reaction is 10 ~ 60 DEG C, preferably 30 ~ 50 DEG C; Reaction times is 3 ~ 20 hours, is preferably 7 ~ 11 hours.
Step B or step e: formula (c-1) or formula (c-2) compound are protected amino in the basic conditions, correspondingly obtain formula (b-1) or formula (b-2) compound.
Wherein used protecting group is carbalkoxy, aralkoxycarbonyl, alkene hydrocarbon carbonyl oxygen, alcoxyl carbobenzoxy; Be preferably tertbutyloxycarbonyl, carbobenzoxy-(Cbz), allyloxycarbonyl, to methoxybenzyloxycarbonyl.The consumption of used blocking group and the mole dosage of formula (c-1) or formula (c-2) compound are than being (1.0 ~ 2.0): 1.
The organic bases of wherein said formation alkaline condition is preferably triethylamine, pyridine, diisopropylethyl amine, and used catalyzer is DMAP; Mineral alkali is preferably sodium carbonate, sodium bicarbonate, salt of wormwood, saleratus.The consumption of alkali and the mole dosage of described formula (c-1) or described formula (c-2) compound are than being (1 ~ 2.3): the mole dosage of Isosorbide-5-Nitrae-Dimethylamino pyridine and described formula (c-1) or described formula (c-2) compound is than being (0.05 ~ 0.15): 1.
This reaction solvent for use is ether solvent, is preferably tetrahydrofuran (THF), methyl tertiary butyl ether; Described solvent load is 10 ~ 35 times of described formula (c-1) or described formula (c-2) compound.
The temperature of reaction of described reaction is 0 ~ 30 DEG C; Reaction times is 5 ~ 24 hours, is preferably 7 ~ 12 hours.
Step C or step F: formula (b-1) or formula (b-2) compound carry out the formula that is obtained by reacting (a-1) or formula (a-2) compound, i.e. butylene oxide ring compounds in the basic conditions.
Wherein said alkali is alkali metal base, is specially sodium hydroxide, potassium hydroxide, sodium carbonate, salt of wormwood, sodium bicarbonate, saleratus; The mole dosage of the consumption of described alkali metal base and formula (a-1) or formula (a-2) compound is than being (1.5 ~ 4.5): 1.
This reaction so solvent is alkane solvents, aromatic hydrocarbon solvent, chlorinated solvent, ether solvent and alcoholic solvent, be preferably normal hexane, toluene, methylene dichloride, tetrahydrofuran (THF), ethanol, methyl alcohol; Described solvent is 10 ~ 40 times of described formula (a-1) or formula (a-2) compound amount.
The temperature of reaction of described reaction is 10 ~ 50 DEG C; Reaction times is 3 ~ 10 hours.
The 2R of what the present invention provided prepare configuration reversal, the method of 3S configuration butylene oxide ring compounds, reaction raw materials is the industrial 2S that can not make full use of, the monochloromethyl alcohol compound of 3S configuration, present invention, avoiding the sulfonyl halides compound using and there is pungency stench sulfur-bearing, the present invention it also avoid use simultaneously and has irritating smell and expensive three halogen acetate compounds, in addition, also can utilize the technical scheme in the present invention, with 2R, the monochloromethyl alcohol compound of 3R configuration is the 2S that 2 upper configuration reversals prepared by raw material, 3R configuration butylene oxide ring compounds.Therefore, the present invention, preparing in butylene oxide ring compounds, can effectively reduce the pollution to environment, and it is simple to have reaction type, react completely, reaction conditions relaxes, and obtains product yield high, cost is low, is easy to the feature of technology, has very high industrial application and economic worth.
Embodiment
Content for a better understanding of the present invention, is described further below in conjunction with specific embodiment.
Embodiment 1:(4S, 5R) preparation of-4-benzyl-5-chloromethyl-2-oxazolidone
(2S, 3S)-3-t-butoxycarbonyl amino-1-chlorine-2-hydroxyl-4-phenyl butane (10.0g, 33.4 mmol) is added in 100mL anhydrous methyl tertbutyl ether, at 10 DEG C, slowly drips SOCl
2(12.1mL, 167.0mmol), after dropwising, is then heated to 50 DEG C by reaction mixture, reacts 8 hours under this temperature of reaction.Be cooled to 0 DEG C after completion of the reaction, use saturated NaHCO
3solution cancellation is reacted, separatory, and organic phase is concentrated into the t-butyl methyl ether solution that 100mL obtains (4S, 5R)-4-benzyl-5-chloromethyl-2-oxazolidone, and concentration is 33.4mol/L, is directly used in next step reaction.
Embodiment 2:(4S, 5R) preparation of-4-benzyl-5-chloromethyl-3-tertbutyloxycarbonyl-2-oxazolidone
Get (the 4S obtained in the reaction of 50mL previous step, 5R) t-butyl methyl ether solution (the 50ml of-4-benzyl-5-chloromethyl-2-oxazolidone, 16.7mmol), add triethylamine (2.6mL, 18.0mmol), tert-Butyl dicarbonate (3.64g, 16.7mmol) and
dMAP(1.95g, 1.6mmol), reaction mixture stirs 8 hours at 15 DEG C.Filter after completion of the reaction and obtain solid-state (4S, 5R)-4-benzyl-5-chloromethyl-3-tertbutyloxycarbonyl-2-oxazolidone 5.28g, yield is 97.1%.
1H NMR(500 MHz，CDCl
3)δ 7.37-7.32(m，2H)，7.30(dt，J＝9.6，4.3 Hz，1H)，7.19(dd，J＝5.1，3.3 Hz，2H)，4.42-4.35(m，2H)，3.49(dd，J＝11.9，5.8 Hz，1H)，3.35(dd，J＝13.5，3.5 Hz，1H)，3.29(dd，J＝11.9，3.7 Hz，1H)，2.84(dd，J＝13.5，9.3 Hz，1H)，1.60(s，9H).MS-ESI：348.1(M+Na
+)
Embodiment 3:(2R, 3S) preparation of-3-t-butoxycarbonyl amino-1,2-epoxy-benzene butane
By (4S, 5R)-4-benzyl-5-chloromethyl-3-tertbutyloxycarbonyl-2-oxazolidone (2.0g, 6.2mmol) join in 5mL ethanol, again by potassium hydroxide (0.70g, 12.4mmol) be dissolved in 5mL ethanol, this potassium hydroxide-ethanol solution is slowly added drop-wise to (4S, 5R) in-4-benzyl-5-chloromethyl-3-tertbutyloxycarbonyl-2-oxazolidone Alcohol system, after dropwising, reaction mixture continues reaction 5 hours at 20 DEG C, react complete, removal of solvent under reduced pressure, resistates is dissolved in 20mL ethyl acetate, extraction, organic phase concentrates to obtain colourless oil liquid (2R, 3S)-3-t-butoxycarbonyl amino-1, 2-epoxy-benzene butane 1.56g, productive rate 95.2%, HPLC purity 99.3%, this oily liquids places curable white solid at-20 DEG C.
1H NMR(500 MHz，CDCl
3)δ 7.34-7.28(m，2H)，7.28-7.21(m，3H)，4.49(s，1H)，4.13(d，J＝6.6 Hz，1H)，3.05-2.99(m，1H)，2.96(d，J＝5.9 Hz，1H)，2.88(dd，J＝13.4，8.0 Hz，1H)，2.70(t，J＝4.4 Hz，1H)，2.58(s，1H)，1.39(s，9H).
MS-ESI：286.1(M+Na
+)
Embodiment 4:(4S, 5R) preparation of-4-benzyl-5-chloromethyl-2-oxazolidone
Operate with method according to the method for embodiment 1, take (2S, 3S)-3-t-butoxycarbonyl amino-1-bromo-2-hydroxy-4-phenyl butane (10.0g, 29.1mmol) add in 100mL anhydrous tetrahydro furan, obtain 100mL (4S, 5R) the tetrahydrofuran solution of-4-benzyl-5-chloromethyl-2-oxazolidone, concentration is 29.1mol/L, can be directly used in next step reaction.
Embodiment 5:(4S, 5R) preparation of-4-benzyl-5-brooethyl-3-tertbutyloxycarbonyl-2-oxazolidone
Operate with method according to the method for embodiment 2, get 50mL4S, 5R) tetrahydrofuran solution of-4-benzyl-5-chloromethyl-2-oxazolidone, after completion of the reaction, obtain (4S, 5R)-4-benzyl-5-brooethyl-3-tertbutyloxycarbonyl-2-oxazolidone 5.31g, yield is 98.3%.
Embodiment 6:(4S, 5R) preparation of-4-benzyl-5-chloromethyl-2-oxazolidone
Operate with method according to the method for embodiment 1, take (2S, 3S)-3-benzyloxycarbonyl amino-1-chlorine-2-hydroxyl-4-phenyl butane (10.0g, 29.9mmol), the t-butyl methyl ether solution that concentration is (4S, 5R)-4-benzyl-5-chloromethyl-2-oxazolidone of 29.9mol/L is obtained after reaction solution concentrates.
Embodiment 7:(4S, 5R)-4-benzyl-5-chloromethyl-3-carbobenzoxy-(Cbz)-2-oxazolidone
Operate with method according to the method for embodiment 2, take 25mL (4S, 5R) the t-butyl methyl ether solution of-4-benzyl-5-chloromethyl-2-oxazolidone, add chloroformic acid benzyl ester (1.27g, 7.48mmol), obtain (4S, 5R)-4-benzyl-5-chloromethyl-3-carbobenzoxy-(Cbz)-2-oxazolidone 2.51g, yield is 93.5%.
Embodiment 8:(4S, 5R) preparation of-4-(4-nitrobenzyl)-5-chloromethyl-2-oxazolidone
Operate with method according to the method for embodiment 1, get (2S, 3S)-3-t-butoxycarbonyl amino-1-chlorine-2-hydroxyl-4-(4-nitrophenyl) butane (10g, 26.4mmol), the t-butyl methyl ether solution of (4S, 5R)-4-(4-the nitrobenzyl)-5-chloromethyl-2-oxazolidone that 100mL concentration is 26.4mmol/L is obtained after reacting complete concentrating.
Embodiment 9:(4S, 5R) preparation of-4-(4-nitrobenzyl)-5-chloromethyl-3-tertbutyloxycarbonyl-2-oxazolidone
Operate with method according to the method for embodiment 2, get (the 4S that concentration is 26.4mmol/L, 5R) the t-butyl methyl ether solution 25mL of-4-(4-nitrobenzyl)-5-chloromethyl-2-oxazolidone, add tert-Butyl dicarbonate (1.5g, 6.88mmol), after completion of the reaction, (4S is obtained, 5R)-4-(4-nitrobenzyl)-5-chloromethyl-3-tertbutyloxycarbonyl-2-oxazolidone 2.43g, yield is 91.1%.
Embodiment 10:(2R, 3S) preparation of-3-t-butoxycarbonyl amino-1,2-epoxy-(4-nitrophenyl) butane
Operate with method according to the method for embodiment 3, get (4S, 5R)-4-(4-nitrobenzyl)-5-chloromethyl-3-tertbutyloxycarbonyl-2-oxazolidone (2g, 4.94mmol), obtain (2R, 3S)-3-t-butoxycarbonyl amino-1,2-epoxy-(4-nitrophenyl) butane 1.43g, yield is 94.1%.
Embodiment 11:(4R, 5S) preparation of-4-benzyl-5-chloromethyl-2-oxazolidone
Operate with method according to the method for embodiment 1, get (2R, 3R)-3-t-butoxycarbonyl amino-1-chlorine-2-hydroxyl-4-phenyl butane (10.0g, 33.4mmol), obtain (2R, 3R)-3-t-butoxycarbonyl amino-1-chlorine-2-hydroxyl-4-phenyl butane t-butyl methyl ether solution 100mL that concentration is 33.4mol/L.
Embodiment 12:(4R, 5S) preparation of-4-benzyl-5-chloromethyl-3-tertbutyloxycarbonyl-2-oxazolidone
Operate with method according to the method for embodiment 2, get (the 4R obtained in the reaction of 50mL previous step, 5S) t-butyl methyl ether solution (the 50ml of-4-benzyl-5-chloromethyl-2-oxazolidone, 16.7mmol), obtain (4R, 5S)-4-benzyl-5-chloromethyl-3-tertbutyloxycarbonyl-2-oxazolidone 5.29g, yield is 97.3%.
Embodiment 13:(2S, 3R) preparation of-3-t-butoxycarbonyl amino-1,2-epoxy-benzene butane
Operate with method according to the method for embodiment 3, get (4R, 5S)-4-benzyl-5-chloromethyl-3-tertbutyloxycarbonyl-2-oxazolidone (2.0g, 6.2mmol), obtain (2S, 3R)-3-t-butoxycarbonyl amino-1,2-epoxy-benzene butane 1.55g, yield is 94.7%.
In sum, the present invention relates to the preparation method of the butylene oxide ring compounds of configuration reversal, relate to (2R especially, 3S) the preparation method of the butylene oxide ring compounds of configuration, above-mentioned preparation method is by 2S, 3S or 2R, the formula (d-1) of 3R configuration or formula (d-2) compound and chlorination reagent carry out ring and are obtained by reacting formula (c-1) or formula (c-2) compound, then in the basic conditions protection is carried out to the amino of the formula obtained (c-1) or (c-2) compound and obtain formula (b-1) or formula (b-2) compound, the formula (b-1) obtained or formula (b-2) compound carry out epoxidation reaction in the basic conditions, obtain formula (a-1) or formula (a-2) compound, i.e. 2R, 3S or 2S, the butylene oxide ring compounds of 3R configuration.
It should be noted that all documents mentioned in the present invention are quoted as a reference in this application, just quoted separately as a reference as each section of document.In addition should understand, the above-described know-why being specific embodiments of the invention and using, after having read foregoing of the present invention, those skilled in the art can make various changes or modifications the present invention and not deviate from spirit of the present invention and scope, and these equivalent form of values fall within the scope of the invention equally.
Claims (5)
1. there is the preparation method as shown in the formula (b-1) compound, comprise step:
Steps A: formula (d-1) compound and sulfur oxychloride carry out ring-closure reaction and prepare formula (c-1) compound in ether solvent,
Step B: formula (c-1) compound carries out protection to amino and obtains formula (b-1) compound under the existence of organic bases and catalyzer,
Wherein said organic bases is triethylamine, pyridine or diisopropylethyl amine, and described catalyzer is DMAP;
Wherein: R
1for phenyl;
R
2for the tertiary butyl;
X is Cl, Br.
2. there is the preparation method as shown in the formula (a-1) compound, comprise step:
Steps A: formula (d-1) compound and sulfur oxychloride carry out ring-closure reaction and prepare formula (c-1) compound in ether solvent,
Step B: formula (c-1) compound carries out protection to amino and obtains formula (b-1) compound under the existence of organic bases and catalyzer,
Wherein said organic bases is triethylamine, pyridine or diisopropylethyl amine, and described catalyzer is DMAP;
Step C: formula (b-1) compound carries out ring-closure reaction and obtains formula (a-1) compound under alkali metal base exists,
Wherein said alkali metal base is sodium hydroxide, potassium hydroxide, sodium carbonate, salt of wormwood, sodium bicarbonate or saleratus;
Wherein: R
1, R
2, the definition of X is identical with the definition of claim 1.
3. there is the preparation method as shown in the formula (b-1) compound, comprising:
Step B: formula (c-1) compound carries out protection to amino and obtains formula (b-1) compound under the existence of organic bases and catalyzer,
Wherein said organic bases is triethylamine, pyridine or diisopropylethyl amine, and described catalyzer is DMAP;
Wherein: R
1, R
2, the definition of X is identical with the definition of claim 1.
4. there is the preparation method as shown in the formula (a-1) compound, comprise step:
Step B: formula (c-1) compound carries out protection to amino and obtains formula (b-1) compound under the existence of organic bases and catalyzer,
Wherein said organic bases is triethylamine, pyridine or diisopropylethyl amine, and described catalyzer is DMAP;
Step C: formula (b-1) compound carries out ring-closure reaction and obtains formula (a-1) compound under alkali metal base exists,
Wherein said alkali metal base is sodium hydroxide, potassium hydroxide, sodium carbonate, salt of wormwood, sodium bicarbonate or saleratus;
Wherein: R
1, R
2, the definition of X is identical with the definition of claim 1.
5. there is the preparation method as shown in the formula (a-2) compound, comprising:
Step D: formula (d-2) compound and sulfur oxychloride carry out ring-closure reaction and obtain formula (c-2) compound in ether solvent,
Step e: formula (c-2) compound carries out protection to amino and obtains formula (b-2) compound under the existence of organic bases and catalyzer,
Wherein said organic bases is triethylamine, pyridine or diisopropylethyl amine, and described catalyzer is DMAP;
Step F: formula (b-2) compound carries out ring-closure reaction and obtains formula (a-2) compound under alkali metal base exists,
Wherein said alkali metal base is sodium hydroxide, potassium hydroxide, sodium carbonate, salt of wormwood, sodium bicarbonate or saleratus;
Wherein: R
1, R
2, the definition of X is identical with the definition of claim 1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010199114.5A CN102276545B (en) | 2010-06-10 | 2010-06-10 | Method for preparing epoxybutane compounds and intermediates thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010199114.5A CN102276545B (en) | 2010-06-10 | 2010-06-10 | Method for preparing epoxybutane compounds and intermediates thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102276545A CN102276545A (en) | 2011-12-14 |
| CN102276545B true CN102276545B (en) | 2015-06-10 |
Family
ID=45102333
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201010199114.5A Active CN102276545B (en) | 2010-06-10 | 2010-06-10 | Method for preparing epoxybutane compounds and intermediates thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102276545B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1050532A2 (en) * | 1999-05-03 | 2000-11-08 | Aerojet Fine Chemicals LLC | Preparation of S,S and R,S amino acid isosteres |
| EP1777213A1 (en) * | 2005-10-18 | 2007-04-25 | Ajinomoto Co., Inc. | Production method of aminochlorohydrin sulfate |
-
2010
- 2010-06-10 CN CN201010199114.5A patent/CN102276545B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1050532A2 (en) * | 1999-05-03 | 2000-11-08 | Aerojet Fine Chemicals LLC | Preparation of S,S and R,S amino acid isosteres |
| EP1777213A1 (en) * | 2005-10-18 | 2007-04-25 | Ajinomoto Co., Inc. | Production method of aminochlorohydrin sulfate |
Non-Patent Citations (1)
| Title |
|---|
| A NEW FACILE DIASTEREOCONVERSION OF 2-AMINO ALCOHOLS INVOLVING A NOVEL CYCLOCARBAMATIO;Shinzo Kano et al.;《Tetrahedron Letters》;19871231;第28卷(第50期);第6331-6334页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102276545A (en) | 2011-12-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2788673T3 (en) | Preparation process of N-boc biphenyl alaninol | |
| CN102933570B (en) | Method for producing (2r)-2-fluoro-2-c-methyl-d-ribono-y-lactone precursor | |
| RU2011115572A (en) | GROUP OF AMINO SUBSTITUTED BENZOYL DERIVATIVES, THEIR PRODUCTION AND APPLICATION | |
| EP3080086B1 (en) | Process of making adamantanamides | |
| CN102002021A (en) | Novel method for synthesizing repaglinide | |
| Ghosh et al. | Cyclic sulfolanes as novel and high-affinity P2 ligands for HIV-1 protease inhibitors | |
| CN114456101A (en) | Synthesis method of key intermediate for synthesizing PF-07321332 | |
| CN1880302A (en) | Method for synthesizing isorhodanate | |
| CN105330600A (en) | Preparation method for Regorafenib hydrate | |
| CN102276545B (en) | Method for preparing epoxybutane compounds and intermediates thereof | |
| Zhang et al. | Dramatic solvent effect in the one-pot synthesis of substituted ureas directly from primary alcohols using the combined reagent of iodobenzene dichloride and sodium azide in ethyl acetate | |
| Das et al. | Stereoselective direct reductive amination of ketones with electron-deficient amines using Re 2 O 7/NaPF 6 catalyst | |
| CA2373530A1 (en) | Taxane derivatives and processes for the preparation thereof | |
| JP2012184228A (en) | α-KETO ACID ESTER COMPOUND HAVING CHIRAL CENTER AT γ-POSITION AND SYNTHESIS METHOD THEREOF | |
| CN102002012A (en) | Method for synthesizing 1,3-oxazole-2,4-diketone compounds | |
| JPH04275263A (en) | Stereoregulated preparation of hydroxy ester, hydroxy amide and lactone compound from chiral alpha-aminoaldehyde | |
| ES2288743T3 (en) | PROCEDURE FOR THE PREPARATION OF ALCOXICARBONILMETOXI-CICLOPENTANOS. | |
| CN105713068B (en) | Method for preparing imidapril key intermediate and derivative thereof | |
| KR20200038938A (en) | Method for preparing cyclic carbonate | |
| CN106748884B (en) | Preparation method of bicalutamide intermediate | |
| CN109265431B (en) | Synthesis process of 3-acetyl-10, 11-dihydro-5H-dibenzo [ C, G ] chromen-8 (9H) -one | |
| JPWO2004002973A1 (en) | Process for producing optically active 1-substituted amino-2,3-epoxypropane, synthetic intermediate thereof, and process for producing them | |
| CN102212040A (en) | Novel preparation method for chiral 2-hydroxymethyl morpholine compounds | |
| CN103012122A (en) | Preparation method of 2-chloro-5-(trifluoromethyl) benzoic acid | |
| CN105175406A (en) | HCV inhibitor intermediates and method for preparation of HCV inhibitor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |